ADC THERAPEUTICS SA (ADCT)       4.63  -0.27 (-5.51%)

4.63  -0.27 (-5.51%)

CH0499880968 - Common Stock

ADC THERAPEUTICS SA4.63

NYSE:ADCT (2/3/2023, 7:23:25 PM)-0.27 (-5.51%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) 11-08 2022-11-08/bmo Earnings (Next) N/A N/A
Ins Owners N/A Inst Owners 49.6%
Market Cap 356.10M Shares 76.91M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 77.14
IPO 05-15 2020-05-15

Stock Screener Links

Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ADCT Daily chart

Company Profile

ADC Therapeutics SA is a clinical-stage biotechnology company. The company is headquartered in Epalinges, Vaud and currently employs 312 full-time employees. The company went IPO on 2020-05-15. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.

Company Info

ADC THERAPEUTICS SA

Biopole, route de la Corniche 3B

Epalinges VAUD 1066

P: 41216530200.0

CEO: Christopher Martin

Employees: 312

Website: https://adctherapeutics.com/

ADCT News

News Image3 days ago - Seeking AlphaADC Therapeutics stock slips after pricing stock offering by seller (NYSE:ADCT)

ADC Therapeutics (ADCT) shares fell over 6% premarket on Thursday after the biotechnology company announced pricing of an underwritten offering of 12M common shares by A.T

News Image3 days ago - ADC Therapeutics SAADC Therapeutics Announces Pricing of Underwritten Offering by a Selling ShareholderNews Image4 days ago - ADC Therapeutics SAADC Therapeutics to Participate in February Investor ConferencesNews Imagea month ago - Seeking AlphaIntoCell enters development and license option agreement with ADC Therapeutics (NYSE:ADCT)

IntoCell signed a Material Transfer Agreement (or MTA) with option to license with ADC Therapeutics SA (ADCT).Under the agreement, IntoCell, a South Korean biotech developing novel...

News Imagea month ago - PharmaVenturesPharmaVentures advises IntoCell on Development and License Option Agreement with ADC Therapeutics

/PRNewswire/ -- PharmaVentures is pleased to announce that it acted as exclusive advisor for IntoCell on its agreement with ADC Therapeutics (NYSE: ADCT)....

News Imagea month ago - IntoCellIntoCell Enters into Development and License Option Agreement with ADC Therapeutics

/PRNewswire/ -- IntoCell today announced the signing of a Material Transfer Agreement (MTA) with option to license with ADC Therapeutics SA (NYSE: ADCT). Under...

ADCT Twits

Here you can normally see the latest stock twits on ADCT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example